PROteKT logo

PROteKT

Randomised, Controlled, Open-Label Trial Of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in CF

PROteKT

Randomised, Controlled, Open-Label Trial Of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in CF
Funding The J P Moulton Charitable Foundation
Portfolio Paediatric, foetal and maternal health
Interventions Medicine
Randomised Yes
Status Completed
Start Date 13-Oct-2014

Cystic fibrosis is a genetic condition where the lungs and digestive system gets clogged with thick sticky mucus. Many children with cystic fibrosis (CF) have treatment with an antibiotic called tobramycin given straight into the blood stream (called intravenous or IV). This helps treat their lung infections, but it can sometimes cause kidney problems. It is thought that giving a medicine called rosuvastatin at the same time as tobramycin could help protect the kidneys from damage and make it safer to give tobramycin. To find out whether this is true or not, a research study was carried out  in children with CF getting IV tobramycin, where half of the children taking part also get rosuvastatin, and the other half do not.

Publications

  • N/A not published yet